RE: CODE30 Nov 2021 09:52
Also from the 18th December RNS. Its very clearly written that a deal would expected to be agreed almost immidiately. Once again, where is the mention of the peer review. SGS and Vela need to update us exactly what is happening. I stand by my original comment. The lack of an update is a disgrace from all involved.
This gives AZD1656 longevity as a treatment beyond the current pandemic. AZD1656 is an orally available tablet that is stable at room temperature, making it suitable for use around the world. Furthermore, should the trial be successful, we expect to agree a commercial deal with a partner almost immediately."